in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
CPhI: Aesica to triple API sales in three years, to acquire assets in North America and India next year
4:59 AM MDT | October 15, 2012 | Deepti Ramesh in Madrid
Aesica Pharmaceuticals (Newcastle, UK), a provider of active pharmaceutical ingredients (APIs), formulations, and custom synthesis, says that it plans to triple annual revenues from the company’s API business by 2015. Aesica recorded total sales of about $250 million in 2011 and the company’s API business has annual sales of about $50 million. “We have a focused plan to increase the annual API revenues to at least $150 million by the end of 2015, and this will be through a mix of organic and inorganic growth,” Kevin Cook, managing...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee